HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Aesthetic Medicine

1,153.620

-49.823-4.14%

Number of Gainers:1

Number of Losers:9

Number of Flat:3

PE:- -

High:1,202.641

Open:1,202.496

Low:1,144.395

Close:1,203.443

Volume:88.03M

Turnover:777.97M

Market Cap:191.16B

Float Cap:143.21B

Loading ...

BRIEF-CMS Says NDA For Additional Indication Atopic Dermatitis For Ruxolitinib Phosphate Cream Accepted

CMS (867.HK/8a8.SG): Nda for Additional Indication Atopic Dermatitis (Ad) for Ruxolitinib Phosphate Cream Accepted and Granted Priority Review in China

THOMSON REUTERS

China Medical System Holdings - Review Timeline Shortened From 200 Days to 130 Days

THOMSON REUTERS

Ruili Border Crossing Records Over 110,000 Passenger Trips During Spring Festival

China Medical System Holdings Limited Nda for Additional Indication Ad for Ruxolitinib Cream Accepted and Granted Priority Review in China

THOMSON REUTERS

CMS Receives NMPA Acceptance and Priority Review for Ruxolitinib Cream's Atopic Dermatitis Application

China Medical System - Gets Acceptance From China's Nmpa for New Drug Application of Ruxolitinib Phosphate Cream for Treatment of Atopic Dermatitis

THOMSON REUTERS

China Medical System unit Dermavon wins China priority review for ruxolitinib cream in atopic dermatitis

ANGELALIGN (06699) Asserts European Court's Preliminary Ruling on Specific Software Feature Has Minimal User Impact

Assessing China Medical System Holdings (SEHK:867) Valuation After New Lidoderm Rights And AI Drug Discovery Deal

Simply Wall St.

Xuanzhu Biopharmaceutical to Join Hang Seng Index

MT Newswires Live

Xuanzhu Biopharmaceutical Joins Hang Seng Composite IndexXuanzhu Biopharmaceutical Co., Ltd. said it will be included as a constituent stock of the Hang Seng Composite Index following Hang Seng Indexes’ quarterly review, with the change taking effect on March 9, 2026

A Look At Sihuan Pharmaceutical Holdings Group (SEHK:460) Valuation After New Earnings Guidance And Segment Growth

Simply Wall St.

AI Drug Discovery Push And New Kidney Drug Trial Could Be A Game Changer For China Medical System Holdings (SEHK:867)

Simply Wall St.

Assessing China Medical System Holdings (SEHK:867) Valuation After New Kidney Trial Approval And AI Drug Discovery Deal

Simply Wall St.

Shareholder Reduction Plan at HAOHAI BIOTEC Draws Scrutiny, Stock Faces Near-term Pressure

China Medical System Expands AI Drug Pipeline As Valuation Gap Persists

Simply Wall St.

Fosun Pharma Unit Gets China Acceptance for Anesthesia Drug Application

MT Newswires Live

FOSUN PHARMA's Cisplatin Injection Marketing Application Accepted for Review

Fosun Pharma Gets Regulatory Approval for Myeloma Drug Trial

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BK1593/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1593","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1593\",,,,,undefined,":{"symbol":"BK1593","market":"HK","secType":"PLATE","nameCN":"Aesthetic Medicine","latestPrice":1153.6196,"timestamp":1771920487216,"preClose":1203.4431,"halted":0,"volume":88028152,"delay":0,"changeRate":-0.041401,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Not Yet Opened","change":-49.823486,"latestTime":"02-24 16:00:00","open":1202.4957,"high":1202.641,"low":1144.3951,"amount":777973477,"amplitude":0.048399,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1771983000000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1771896600000,1771905600000],[1771909200000,1771920000000]],"pbRate":1.722097,"peRate":24.800202,"turnoverRate":0.004201,"increases":1,"decrements":9,"flats":3,"marketCap":191160162144,"floatMarketCap":143212289952},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1593\",,,,,undefined,":{"symbol":"BK1593","high":1202.641,"amplitude":0.048399,"preClose":1203.4431,"low":1144.3951,"pbRate":"1.722097","latestPrice":1153.6196,"volume":88028152,"delay":0,"open":1202.4957,"prevYearClose":1094.978,"prevWeekClose":1191.344,"prevMonthClose":1146.099,"prevQuarterClose":1094.978,"fiveDayClose":1181.819,"twentyDayClose":1123.018,"sixtyDayClose":1254.994,"secType":"PLATE","market":"HK","turnoverRate":0.004201,"peRate":24.800202,"marketCap":191160162144,"floatMarketCap":143212289952,"timestamp":1771920487216,"nameCN":"Aesthetic Medicine"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1593\",,,,undefined,":{"bkCode":"BK1593","up":1,"down":9,"flat":3},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1593\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2613712416","title":"BRIEF-CMS Says NDA For Additional Indication Atopic Dermatitis For Ruxolitinib Phosphate Cream Accepted","url":"https://stock-news.laohu8.com/highlight/detail?id=2613712416","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613712416?lang=en_us&edition=fundamental","pubTime":"2026-02-24 21:54","pubTimestamp":1771941265,"startTime":"0","endTime":"0","summary":"BRIEF-CMS Says NDA For Additional Indication Atopic Dermatitis For Ruxolitinib Phosphate Cream AcceptedFeb 24 (Reuters) - China Medical System Holdings Ltd 0867.HK:CMS (867.HK/8A8.SG): NDA FOR ADDITIO","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260224:nFWN3ZK18H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999015945.SGD","IE00BVYPNP33.GBP","SG9999004220.SGD","SG9999015986.USD","SG9999015952.SGD","BK1593","00867","LU2488822045.USD","IE00BMCWC346.EUR","BK1191","IE00BGHQDM52.EUR","SG9999015978.USD","IE00BYV24P56.USD","IE00BVYPNQ40.USD"],"gpt_icon":0},{"id":"2613971404","title":"CMS (867.HK/8a8.SG): Nda for Additional Indication Atopic Dermatitis (Ad) for Ruxolitinib Phosphate Cream Accepted and Granted Priority Review in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2613971404","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613971404?lang=en_us&edition=fundamental","pubTime":"2026-02-24 21:35","pubTimestamp":1771940141,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260224:nFWN3ZK18H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IE00BVYPNP33.GBP","SG9999015978.USD","SG9999015986.USD","IE00BMCWC346.EUR","IE00BGHQDM52.EUR","00867","LU2488822045.USD","BK1191","SG9999004220.SGD","IE00BYV24P56.USD","BK1593","SG9999015945.SGD","IE00BVYPNQ40.USD","SG9999015952.SGD"],"gpt_icon":0},{"id":"2613712833","title":"China Medical System Holdings - Review Timeline Shortened From 200 Days to 130 Days","url":"https://stock-news.laohu8.com/highlight/detail?id=2613712833","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613712833?lang=en_us&edition=fundamental","pubTime":"2026-02-24 21:35","pubTimestamp":1771940141,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260224:nFWN3ZK18H:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["00867","LU2488822045.USD","SG9999015945.SGD","IE00BVYPNQ40.USD","BK1191","SG9999015978.USD","SG9999004220.SGD","SG9999015952.SGD","SG9999015986.USD","IE00BVYPNP33.GBP","IE00BMCWC346.EUR","BK1593","IE00BGHQDM52.EUR","IE00BYV24P56.USD"],"gpt_icon":0},{"id":"1173924656","title":"Ruili Border Crossing Records Over 110,000 Passenger Trips During Spring Festival","url":"https://stock-news.laohu8.com/highlight/detail?id=1173924656","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1173924656?lang=en_us&edition=fundamental","pubTime":"2026-02-24 20:05","pubTimestamp":1771934712,"startTime":"0","endTime":"0","summary":"During the Spring Festival holiday period from February 15 to 23, the Ruili immigration border checkpoint recorded a total of 111,800 inbound and outbound passenger trips and 11,400 vehicle crossings...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1593","02135","BK1209"],"gpt_icon":0},{"id":"2613794373","title":"China Medical System Holdings Limited Nda for Additional Indication Ad for Ruxolitinib Cream Accepted and Granted Priority Review in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2613794373","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613794373?lang=en_us&edition=fundamental","pubTime":"2026-02-24 17:53","pubTimestamp":1771926828,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260224:nTUE3RDXWN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IE00BMCWC346.EUR","SG9999015986.USD","IE00BVYPNP33.GBP","SG9999015978.USD","BK1593","LU2488822045.USD","00867","IE00BVYPNQ40.USD","SG9999015945.SGD","SG9999015952.SGD","BK1191","IE00BGHQDM52.EUR","IE00BYV24P56.USD","SG9999004220.SGD"],"gpt_icon":0},{"id":"1104875656","title":"CMS Receives NMPA Acceptance and Priority Review for Ruxolitinib Cream's Atopic Dermatitis Application","url":"https://stock-news.laohu8.com/highlight/detail?id=1104875656","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1104875656?lang=en_us&edition=fundamental","pubTime":"2026-02-24 17:52","pubTimestamp":1771926741,"startTime":"0","endTime":"0","summary":"CMS announced that its subsidiary, Demai Pharmaceutical, a specialist in dermatological health currently pursuing an independent listing on the Main Board of the Hong Kong Stock Exchange, has...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BVYPNQ40.USD","AD","IE00BYV24P56.USD","LU2488822045.USD","SG9999015945.SGD","IE00BGHQDM52.EUR","SG9999015978.USD","06978","BK4132","IE00BVYPNP33.GBP","BK1161","BK1574","SG9999015986.USD","BK1593","IE00BMCWC346.EUR","BK1191","00867","SG9999015952.SGD","SG9999004220.SGD","159992"],"gpt_icon":0},{"id":"2613791083","title":"China Medical System  -  Gets Acceptance From China's Nmpa for New Drug Application of Ruxolitinib Phosphate Cream for Treatment of Atopic Dermatitis","url":"https://stock-news.laohu8.com/highlight/detail?id=2613791083","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613791083?lang=en_us&edition=fundamental","pubTime":"2026-02-24 17:49","pubTimestamp":1771926544,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260224:nFWN3ZK0N5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1191","IE00BMCWC346.EUR","SG9999004220.SGD","LU2488822045.USD","IE00BVYPNP33.GBP","IE00BVYPNQ40.USD","BK1593","SG9999015945.SGD","SG9999015952.SGD","IE00BYV24P56.USD","SG9999015986.USD","00867","IE00BGHQDM52.EUR","SG9999015978.USD"],"gpt_icon":0},{"id":"2613791089","title":"China Medical System unit Dermavon wins China priority review for ruxolitinib cream in atopic dermatitis","url":"https://stock-news.laohu8.com/highlight/detail?id=2613791089","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613791089?lang=en_us&edition=fundamental","pubTime":"2026-02-24 17:48","pubTimestamp":1771926492,"startTime":"0","endTime":"0","summary":"China Medical System Holdings said its subsidiary Dermavon Holdings received acceptance from China’s NMPA for a new drug application seeking an additional indication for ruxolitinib phosphate cream to treat mild to moderate atopic dermatitis, and the filing was granted priority review by the CDE. Dermavon holds an exclusive license from Incyte to develop, register and commercialize the product in Mainland China, Hong Kong, Macau, Taiwan and 11 Southeast Asian countries, with a non-exclusive manufacturing license in the same territory.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. China Medical System Holdings Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Ho","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260224:nNDL4fHG48:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IE00BVYPNQ40.USD","BK4550","00867","IE00BVYPNP33.GBP","SG9999015986.USD","BK4585","SG9999015978.USD","SG9999015945.SGD","BK4588","SG9999004220.SGD","BK1593","BK1191","IE00BMCWC346.EUR","BK4532","LU2488822045.USD","SG9999015952.SGD","IE00BGHQDM52.EUR","INCY","IE00BYV24P56.USD"],"gpt_icon":0},{"id":"1106284354","title":"ANGELALIGN (06699) Asserts European Court's Preliminary Ruling on Specific Software Feature Has Minimal User Impact","url":"https://stock-news.laohu8.com/highlight/detail?id=1106284354","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1106284354?lang=en_us&edition=fundamental","pubTime":"2026-02-24 09:52","pubTimestamp":1771897949,"startTime":"0","endTime":"0","summary":"ANGELALIGN TECHNOLOGY INC. (06699, hereinafter referred to as \"ANGELALIGN\") has stated that a provisional injunction issued by the Unified Patent Court of Düsseldorf, Germany, requiring the company...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1100","VGT","BK4588","BK4585","BK1587","BK1583","06699","BK1593"],"gpt_icon":0},{"id":"2613275621","title":"Assessing China Medical System Holdings (SEHK:867) Valuation After New Lidoderm Rights And AI Drug Discovery Deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2613275621","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613275621?lang=en_us&edition=fundamental","pubTime":"2026-02-24 05:15","pubTimestamp":1771881333,"startTime":"0","endTime":"0","summary":"China Medical System Holdings (SEHK:867) has drawn fresh attention after securing exclusive mainland China distribution rights for Lidoderm lidocaine cataplasms and forming an AI-focused drug discovery partnership with Insilico Medicine across multiple R&D programs.\nSee our latest analysis for China Medical System Holdings.\nThe stock’s recent momentum has been firm, with a 12.45% 1 month share price return and 17.77% year to date share price return. The 1 year total shareholder return of...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-867/china-medical-system-holdings-shares/news/assessing-china-medical-system-holdings-sehk867-valuation-af-2","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-867/china-medical-system-holdings-shares/news/assessing-china-medical-system-holdings-sehk867-valuation-af-2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4585","IE00BMCWC346.EUR","BK1593","IE00BVYPNQ40.USD","SG9999015952.SGD","BK4587","BK4023","BK1191","BK4543","DCF","IE00BVYPNP33.GBP","SG9999015986.USD","00867","BK4551","BK4588","IE00BGHQDM52.EUR","LU2488822045.USD","AI","SG9999004220.SGD","BK4528","AIYY","SG9999015945.SGD","IE00BYV24P56.USD","SG9999015978.USD"],"gpt_icon":0},{"id":"2613083972","title":"Xuanzhu Biopharmaceutical to Join Hang Seng Index","url":"https://stock-news.laohu8.com/highlight/detail?id=2613083972","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613083972?lang=en_us&edition=fundamental","pubTime":"2026-02-23 10:01","pubTimestamp":1771812091,"startTime":"0","endTime":"0","summary":"Sihuan Pharmaceutical Holdings Group  said its non-wholly owned subsidiary Xuanzhu Biopharmaceutical  is due for inclusion to the Hang Seng Composite Index on March 9, according to a Hong Kong bourse filing Friday.Xuanzhu Biopharmaceutical went public in Hong Kong in October of last year.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1593","BK1515","00460","02575","BK1600","BK1191"],"gpt_icon":0},{"id":"2613222177","title":"**Xuanzhu Biopharmaceutical Joins Hang Seng Composite Index**Xuanzhu Biopharmaceutical Co., Ltd. said it will be included as a constituent stock of the Hang Seng Composite Index following Hang Seng Indexes’ quarterly review, with the change taking effect on March 9, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2613222177","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613222177?lang=en_us&edition=fundamental","pubTime":"2026-02-22 18:06","pubTimestamp":1771754767,"startTime":"0","endTime":"0","summary":"**Xuanzhu Biopharmaceutical Joins Hang Seng Composite Index** Xuanzhu Biopharmaceutical Co., Ltd. said it will be included as a constituent stock of the Hang Seng Composite Index following Hang Seng Indexes’ quarterly review, with the change taking effect on March 9, 2026. Xuanzhu Biopharmaceutical Co., Ltd. said it will be **added** as a constituent stock of the **Hang Seng Composite Index** following the Hang Seng Indexes Company’s quarterly review for the period ended Dec. 31, 2025, with the change effective March 9, 2026. The company said the inclusion reflects investor recognition of its value and growth potential and is expected to improve share liquidity and broaden its investor base.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advic","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260222:nNDL2nmBT7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","02575","BK1191","BK1593","BK1600","00460"],"gpt_icon":0},{"id":"2612405689","title":"A Look At Sihuan Pharmaceutical Holdings Group (SEHK:460) Valuation After New Earnings Guidance And Segment Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2612405689","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612405689?lang=en_us&edition=fundamental","pubTime":"2026-02-19 15:42","pubTimestamp":1771486935,"startTime":"0","endTime":"0","summary":"Guidance-driven spotlight on Sihuan Pharmaceutical Holdings Group\nSihuan Pharmaceutical Holdings Group (SEHK:460) caught investor attention after issuing unaudited 2025 earnings guidance, indicating at least RMB 2,500 million in revenue and RMB 150 million in net profit for the year.\nSee our latest analysis for Sihuan Pharmaceutical Holdings Group.\nThe earnings guidance lands after a strong run in the share price, with a 30 day share price return of 25.19% and a year to date gain of 28.12%...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-460/sihuan-pharmaceutical-holdings-group-shares/news/a-look-at-sihuan-pharmaceutical-holdings-group-sehk460-valua","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-460/sihuan-pharmaceutical-holdings-group-shares/news/a-look-at-sihuan-pharmaceutical-holdings-group-sehk460-valua","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["DCF","BK1191","00460","BK1515","BK1600","BK1593"],"gpt_icon":0},{"id":"2612467291","title":"AI Drug Discovery Push And New Kidney Drug Trial Could Be A Game Changer For China Medical System Holdings (SEHK:867)","url":"https://stock-news.laohu8.com/highlight/detail?id=2612467291","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612467291?lang=en_us&edition=fundamental","pubTime":"2026-02-18 04:16","pubTimestamp":1771359400,"startTime":"0","endTime":"0","summary":"In early February 2026, Insilico Medicine announced a partnership with China Medical System Holdings to apply its AI platform to at least two co-developed drug discovery programs, while CMS separately received Chinese regulatory approval to begin human clinical trials of its self-developed complement factor B inhibitor CMS-D017 for complement-mediated kidney diseases.\nTogether, the AI-enabled collaboration and first-in-human trial clearance highlight CMS’s push to build an innovative...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-867/china-medical-system-holdings-shares/news/ai-drug-discovery-push-and-new-kidney-drug-trial-could-be-a","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-867/china-medical-system-holdings-shares/news/ai-drug-discovery-push-and-new-kidney-drug-trial-could-be-a","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1191","IE00BVYPNP33.GBP","BK4023","LU2488822045.USD","SG9999015986.USD","BK4587","IE00BYV24P56.USD","SG9999015978.USD","SG9999015952.SGD","BK4585","BK4543","SG9999004220.SGD","IE00BGHQDM52.EUR","SG9999015945.SGD","AI","BK1593","IE00BVYPNQ40.USD","BK4588","00867","IE00BMCWC346.EUR","BK4551","BK4528"],"gpt_icon":0},{"id":"2611483650","title":"Assessing China Medical System Holdings (SEHK:867) Valuation After New Kidney Trial Approval And AI Drug Discovery Deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2611483650","media":"Simply Wall St.","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611483650?lang=en_us&edition=fundamental","pubTime":"2026-02-16 20:14","pubTimestamp":1771244062,"startTime":"0","endTime":"0","summary":"China Medical System Holdings (SEHK:867) has drawn fresh attention after Chinese regulators cleared human trials for its CMS-D017 kidney disease therapy, alongside a new AI-focused drug discovery partnership with Insilico Medicine.\nSee our latest analysis for China Medical System Holdings.\nThe recent CMS D017 trial clearance and AI drug discovery tie up come as China Medical System Holdings’ share price sits at HK$15.33, with a 30 day share price return of 9.34% and a 1 year total shareholder...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-867/china-medical-system-holdings-shares/news/assessing-china-medical-system-holdings-sehk867-valuation-af-1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-867/china-medical-system-holdings-shares/news/assessing-china-medical-system-holdings-sehk867-valuation-af-1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["SG9999015978.USD","SG9999015952.SGD","IE00BMCWC346.EUR","BK1191","SG9999004220.SGD","LU2488822045.USD","IE00BVYPNQ40.USD","DCF","00867","IE00BVYPNP33.GBP","IE00BGHQDM52.EUR","SG9999015945.SGD","SG9999015986.USD","IE00BYV24P56.USD","BK1593"],"gpt_icon":0},{"id":"1199641082","title":"Shareholder Reduction Plan at HAOHAI BIOTEC Draws Scrutiny, Stock Faces Near-term Pressure","url":"https://stock-news.laohu8.com/highlight/detail?id=1199641082","media":"Deep News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1199641082?lang=en_us&edition=fundamental","pubTime":"2026-02-14 14:01","pubTimestamp":1771048867,"startTime":"0","endTime":"0","summary":"A shareholder reduction plan is currently the most notable event for HAOHAI BIOTEC. On February 12, 2026, the company announced that shareholder Lou Guoliang, due to personal funding requirements,...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1593","06826","BK1161"],"gpt_icon":0},{"id":"2611697251","title":"China Medical System Expands AI Drug Pipeline As Valuation Gap Persists","url":"https://stock-news.laohu8.com/highlight/detail?id=2611697251","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611697251?lang=en_us&edition=fundamental","pubTime":"2026-02-13 22:32","pubTimestamp":1770993144,"startTime":"0","endTime":"0","summary":"China Medical System Holdings (SEHK:867) has partnered with Insilico Medicine to co-develop AI supported drug discovery programs in central nervous system and autoimmune diseases.\nThe company also received clinical trial approval for its selective complement factor B inhibitor CMS-D017 in kidney disease and paroxysmal nocturnal hemoglobinuria.\n\nChina Medical System Holdings, trading at HK$15.13, has seen its share price gain 7.8% over the past month and 15.4% year to date, with a 1 year...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-867/china-medical-system-holdings-shares/news/china-medical-system-expands-ai-drug-pipeline-as-valuation-g","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-867/china-medical-system-holdings-shares/news/china-medical-system-expands-ai-drug-pipeline-as-valuation-g","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["SG9999004220.SGD","SG9999015945.SGD","SG9999015952.SGD","IE00BYV24P56.USD","IE00BMCWC346.EUR","AI","IE00BVYPNQ40.USD","BK1593","BK4551","BK4585","IE00BGHQDM52.EUR","SG9999015986.USD","SG9999015978.USD","BK4587","IE00BVYPNP33.GBP","LU2488822045.USD","BK4023","BK1191","00867","BK4528","BK4588","BK4543"],"gpt_icon":0},{"id":"2611126156","title":"Fosun Pharma Unit Gets China Acceptance for Anesthesia Drug Application","url":"https://stock-news.laohu8.com/highlight/detail?id=2611126156","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611126156?lang=en_us&edition=fundamental","pubTime":"2026-02-13 19:31","pubTimestamp":1770982277,"startTime":"0","endTime":"0","summary":"Shanghai Fosun Pharmaceutical  said unit Jinzhou Avanc Pharmaceutical's drug registration application of Moxetomidate Hydrochloride Injection was accepted by China's National Medical Products Administration, according to a Friday Hong Kong bourse filing.The indication under this application is for the induction and maintenance of anesthesia during short surgical procedures.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["600196","BK0028","BK1593","BK0060","02196","BK1191","BK0183","BK1515","BK0187","BK0175","BK0188","BK0196","BK0012","BK0096","BK0239"],"gpt_icon":0},{"id":"1192481164","title":"FOSUN PHARMA's Cisplatin Injection Marketing Application Accepted for Review","url":"https://stock-news.laohu8.com/highlight/detail?id=1192481164","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1192481164?lang=en_us&edition=fundamental","pubTime":"2026-02-13 17:54","pubTimestamp":1770976456,"startTime":"0","endTime":"0","summary":"FOSUN PHARMA (02196) announced that the marketing authorization application for Cisplatin Injection, submitted by its controlling subsidiary, Gismee (Wuhan) Pharmaceutical Co., Ltd., has been...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0188","BK1515","BK0183","BK0012","BK0175","02196","BK0196","BK0239","600196","BK1191","BK0028","BK0096","BK0187","BK1593","BK0060"],"gpt_icon":0},{"id":"2611747189","title":"Fosun Pharma Gets Regulatory Approval for Myeloma Drug Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2611747189","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611747189?lang=en_us&edition=fundamental","pubTime":"2026-02-13 12:30","pubTimestamp":1770957008,"startTime":"0","endTime":"0","summary":"Shanghai Fosun Pharmaceutical  obtained China's regulatory approval for first phase clinical trials of subcutaneous injection HLX15-SC for multiple myeloma treatment.HLX15 is a daratumumab biosimilar independently developed by the company, according to a Thursday filing with the Shanghai bourse.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0012","BK0196","02196","BK1191","BK0239","BK1593","600196","BK0175","BK0096","BK0060","BK0183","BK0187","BK0028","BK1515","BK0188"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":43,"code":"91000000","status":"200"}]}}